Know Cancer

or
forgot password

Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer


N/A
N/A
N/A
Not Enrolling
Female
Breast Cancer

Thank you

Trial Information

Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer


Inclusion Criteria:



- Provision of informed consent

- Postmenopausal, hormon receptor positive patients with early breast cancer treated
with Arimidex

- Investigators are requested to recruit patients only with at least 1 month prior
Arimidex treatment.

Exclusion Criteria:

- Allergy to substance of medication

- Pre-perimenopausal woman

- Woman not eligible for treatment

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Elements of the investigator questionnaire SF RAND-36 questionnaire

Outcome Time Frame:

Quarterly (plus or minus 3 days )

Safety Issue:

No

Principal Investigator

Zsolt Horváth, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Institute of Oncology

Authority:

Hungary: National Institute of Pharmacy

Study ID:

NIS-OHU-ARI-2007/1

NCT ID:

NCT00692289

Start Date:

June 2008

Completion Date:

July 2010

Related Keywords:

  • Breast Cancer
  • Quality of Life
  • Breast Neoplasms

Name

Location